Summary of patient characteristics and treatment outcomes according to the presence of any mutation
| Patient’s characteristics . | Overall . | Overall patients (n = 254) . | P value . | Imatinib (n = 190) . | P value . | 2G-TKI (n = 64) . | P value . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mutated . | No mutation . | Mutated . | No mutation . | Mutated . | No mutation . | ||||||
| No. of patients (%) | 254 | 57 | 197 | - | 44 | 146 | - | 13 | 51 | ||
| Age, median (range), y | 54 (17-82) | 53.5 (21-82) | 53 (17-82) | .993 | 53.5 (21-77) | 57 (17-82) | .43 | 64.5 (47-82) | 48 (17-81) | .273 | |
| Gender (female:male) | 111/143 (43.7/56.3) | 25/32 (43.8/56.2) | 86/111 (22.5/55.5) | .065 | 17/27 (21.4/78.6) | 66/79 (34.7/65.3) | .097 | 5/8 (38.4/61.5) | 18/31 (35.3/64.7) | .505 | |
| Sokal risk group | Low | 61 (24.0) | 10 (17.5) | 51 (25.5) | .202 | 9 (20.4) | 35 (24.0) | .329 | 1 (0) | 16 (31.4) | |
| Int | 84 (33.1) | 15 (26.3) | 69 (34.5) | 11 (25) | 53 (36.3) | 3 (0) | 16 (31.4) | .329 | |||
| High | 74 (29.1) | 19 (33.3) | 55 (27.5) | 13 (29.5) | 40 (27.3) | 6 (100) | 14 (27.4) | ||||
| Advanced phase | 21 (8.3) | 2 (12.5) | 19 (8.0) | .629 | 2 (14.3) | 16 (9.1) | .627 | 0 (0) | 2 (3.3) | 1.000 | |
| ACAs∗ | 32 (15.7) | 2 (18.2) | 30 (15.5) | .844 | 2 (22.2) | 21 (15.6) | .636 | 0 (0) | 8 (14.0) | 1.000 | |
| Response and long-term outcomes | |||||||||||
| MR2 at 12 mo | 75.4 ± 5.35% | 68.8 (54.6-79.3) | 77.4 (70.7-82.7) | .0283 | 61.8 (45.3-74.6) | 71.6 (63.4-78.3) | .0234 | 92.3 (35.8-99.4) | 93.8 (80.1-98.1) | .672 | |
| MMR at 3 y | 80.9 ± 4.9% | 66.7 (52.1-77.7) | 84.9 (78.8-89.4) | .0101 | 58.6 (41.9-72.0) | 82.3 (74.7-87.8) | .00758 | 92.3 (35.8-99.4) | 92.4 (76.6-97.7) | .787 | |
| MR4 at 5 y | 72.1 ± 5.5% | 59.2 (44.2-71.4) | 75.8 (68.8-81.4) | .0178 | 56.1 (39.0-70.0) | 73.1 (64.7-79.8) | .0231 | 70.3 (29.6-90.3) | 82.9 (67.1-91.5) | .446 | |
| FFS at 3 y | 73.3 ± 1.7% | 61.6 (47.3-73.1) | 76.8 (69.9-82.2) | .00336 | 59.6 (43.2-72.7) | 71.6 (63.2-78.5) | .0257 | 68.4 (35.9-86.8) | 91.6 (79.2-96.8) | .05 | |
| Progression at 5 y | 7.1 ± 1.1% | 9.3 (3.4-19.1) | 6.3 (3.3-10.6) | .0225 | 12.0 (4.3-23.9) | 7.5 (3.8-12.9) | .0227 | 0 | 2.9 (0.2-13.0) | .672 | |
| OS at 10 y | 70.6 ± 6.8% | 59.9 (42.9-73.4) | 74.3 (66.1-80.8) | .0997 | 56.9 (39.3-71.2) | 69.1 (59.4-76.9) | .167 | 80.0 (20.4-96.9) | 92.0 (77.0-97.4) | .772 | |
| Patient’s characteristics . | Overall . | Overall patients (n = 254) . | P value . | Imatinib (n = 190) . | P value . | 2G-TKI (n = 64) . | P value . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mutated . | No mutation . | Mutated . | No mutation . | Mutated . | No mutation . | ||||||
| No. of patients (%) | 254 | 57 | 197 | - | 44 | 146 | - | 13 | 51 | ||
| Age, median (range), y | 54 (17-82) | 53.5 (21-82) | 53 (17-82) | .993 | 53.5 (21-77) | 57 (17-82) | .43 | 64.5 (47-82) | 48 (17-81) | .273 | |
| Gender (female:male) | 111/143 (43.7/56.3) | 25/32 (43.8/56.2) | 86/111 (22.5/55.5) | .065 | 17/27 (21.4/78.6) | 66/79 (34.7/65.3) | .097 | 5/8 (38.4/61.5) | 18/31 (35.3/64.7) | .505 | |
| Sokal risk group | Low | 61 (24.0) | 10 (17.5) | 51 (25.5) | .202 | 9 (20.4) | 35 (24.0) | .329 | 1 (0) | 16 (31.4) | |
| Int | 84 (33.1) | 15 (26.3) | 69 (34.5) | 11 (25) | 53 (36.3) | 3 (0) | 16 (31.4) | .329 | |||
| High | 74 (29.1) | 19 (33.3) | 55 (27.5) | 13 (29.5) | 40 (27.3) | 6 (100) | 14 (27.4) | ||||
| Advanced phase | 21 (8.3) | 2 (12.5) | 19 (8.0) | .629 | 2 (14.3) | 16 (9.1) | .627 | 0 (0) | 2 (3.3) | 1.000 | |
| ACAs∗ | 32 (15.7) | 2 (18.2) | 30 (15.5) | .844 | 2 (22.2) | 21 (15.6) | .636 | 0 (0) | 8 (14.0) | 1.000 | |
| Response and long-term outcomes | |||||||||||
| MR2 at 12 mo | 75.4 ± 5.35% | 68.8 (54.6-79.3) | 77.4 (70.7-82.7) | .0283 | 61.8 (45.3-74.6) | 71.6 (63.4-78.3) | .0234 | 92.3 (35.8-99.4) | 93.8 (80.1-98.1) | .672 | |
| MMR at 3 y | 80.9 ± 4.9% | 66.7 (52.1-77.7) | 84.9 (78.8-89.4) | .0101 | 58.6 (41.9-72.0) | 82.3 (74.7-87.8) | .00758 | 92.3 (35.8-99.4) | 92.4 (76.6-97.7) | .787 | |
| MR4 at 5 y | 72.1 ± 5.5% | 59.2 (44.2-71.4) | 75.8 (68.8-81.4) | .0178 | 56.1 (39.0-70.0) | 73.1 (64.7-79.8) | .0231 | 70.3 (29.6-90.3) | 82.9 (67.1-91.5) | .446 | |
| FFS at 3 y | 73.3 ± 1.7% | 61.6 (47.3-73.1) | 76.8 (69.9-82.2) | .00336 | 59.6 (43.2-72.7) | 71.6 (63.2-78.5) | .0257 | 68.4 (35.9-86.8) | 91.6 (79.2-96.8) | .05 | |
| Progression at 5 y | 7.1 ± 1.1% | 9.3 (3.4-19.1) | 6.3 (3.3-10.6) | .0225 | 12.0 (4.3-23.9) | 7.5 (3.8-12.9) | .0227 | 0 | 2.9 (0.2-13.0) | .672 | |
| OS at 10 y | 70.6 ± 6.8% | 59.9 (42.9-73.4) | 74.3 (66.1-80.8) | .0997 | 56.9 (39.3-71.2) | 69.1 (59.4-76.9) | .167 | 80.0 (20.4-96.9) | 92.0 (77.0-97.4) | .772 | |
Int, intermediate.